Peter Tai-Ching Ho - Oct 24, 2022 Form 4/A - Amendment Insider Report for Aravive, Inc. (ARAV)

Role
Director
Signature
/s/ Abel Svitavsky, Attorney-in-fact
Stock symbol
ARAV
Transactions as of
Oct 24, 2022
Transactions value $
$49,999
Form type
4/A - Amendment
Date filed
10/27/2022, 09:38 PM
Date Of Original Report
Oct 26, 2022
Previous filing
Sep 26, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARAV Common stock Award $50K +54.4K +5435.3% $0.92 55.4K Oct 24, 2022 See footnote F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARAV Series A Warrants (right to buy) Award +27.2K 27.2K Oct 24, 2022 Common stock 27.2K $0.79 See footnote F1, F2, F3, F4
transaction ARAV Series B Warrants (right to buy) Award +27.2K 27.2K Oct 24, 2022 Common stock 27.2K $0.79 See footnote F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 24, 2022, Aravive, Inc. (the "Company") agreed to issue approximately $41.5 million of securities including shares of its common stock and warrants(the "Warrants") to purchase shares of common stock in a private placement transaction (the "Private Placement") to certain investors, including the reporting person. The combined purchase price of each share of common stock and accompanying Warrants is $0.9199.
F2 The shares of common stock and Warrants reported herein are owned directly by the Peter Ho Trust - 2016 U/A 05/27/16 (the "Trust"), of which Peter T. Ho and Hui Ping W. Ho are the Trustees for the benefit of Peter T. Ho. This amendment is being filed to report that the shares of common stock and Warrants are held indirectly by the Trust.
F3 The Series A Warrants are exercisable at any time after the Authorized Share Increase (as defined below) and will expire on the date that is the later of (i) fifteen (15) months after the date of the Authorized Share Increase, or (ii) one (1) month after public announcement by or on behalf of the Company of the publication of top line data from the Company's Phase 3 trial of batiraxcept in platinum-resistant ovarian cancer.
F4 In connection with the Private Placement, the Company has agreed to convene a special meeting of its stockholders or to seek written consent of the stockholders no later than 120 days following the closing of the Private Placement to seek approval of an increase in the number of the Company's authorized shares of common stock pursuant to an amendment to the Company's Certificate of Incorporation (such increase, the "Authorized Share Increase") to allow for full sufficient authorized and unissued shares of common stock for the full exercise of all of the Warrants and the shares of common stock issuable upon exercise thereof.
F5 The Series B Warrants are exercisable at any time after the Authorized Share Increase and will expire thirty (30) months after the Authorized Share Increase.